Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc has demonstrated significant financial growth with its Q3 revenue reaching $18,942, marking a 31% year-over-year increase, primarily attributed to an 89% rise in Nociscan report volumes. The company is making notable strides in the market, evidenced by substantial commercial agreements with reputable healthcare providers such as Scripps Health and affiliates of RadNet, which enhances its revenue-generating capabilities through increased adoption of the Nociscan platform. The ongoing CLARITY trial and favorable coverage developments in the UK are expected to further drive momentum, indicating a strong potential for continued growth in both revenues and market presence.

Bears say

Aclarion Inc faces significant challenges that justify a negative outlook on its stock, primarily due to slower-than-expected market traction with both surgeons and payers, which could hinder revenue growth from its sole product, the Nociscan platform. The company is also experiencing rising marketing and administrative expenses, leading to downward adjustments in its fiscal year 2025 earnings per share (EPS) estimates, which reflect a continuous increase in operating costs. Additionally, notable risks such as balance sheet/liquidity concerns, regulatory approval hurdles, and competitive pressures further complicate Aclarion's path to sustainable profitability.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.